Personalized heart ablation may beat standard treatment for AFib

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years on the date of consent for the trial. 2. Subjects must have paroxysmal AF with at least one episode of AF over the past 12 months (patients on antiarrhythmic medications do not need to satisfy this criterion). At least one episode of AF documented on 12-lead ECG, Holter monitor, Trans-telephonic monitor (TTM) or Loop Recorder. 3. Subjects must be able to provide informed consent. Exclusion Criteria: 1. Persistent and permanent AF. 2. History of previous catheter or surgical ablation for AF, AFl, AT, Atrioventricular Nodal Reentrant Tachycardia (AVNRT), Atrioventricular Reentrant Tachycardia (AVRT). 3. Documented AVNRT, AVRT, AT or Atrial Flutter prior to enrolment in the trial. 4. Previous left atrial (LA) ablation or LA surgery. 5. Previous pulmonary vein stenosis or pulmonary vein stent. 6. Pre-existing hemi-diaphragmatic paralysis. 7. Active intracardiac thrombus. 8. Contraindication to systemic oral anticoagulation therapy 9. Current immunosuppressant therapy (corticosteroids, biologic immunomodulators; such patients may be considered if they can safely discontinue immunosuppressants for three months prior to and for three months following catheter ablation). 10. Reversible causes of AF (e.g., uncontrolled hyperthyroidism, within six months of cardiac surgery). 11. Left ventricular ejection fraction \<35%. 12. NYHA Class 4 heart failure. 13. Hypertrophic cardiomyopathy 14. Significant valve disease (moderate or severe mitral/aortic stenosis or regurgitation). 15. Patients with mechanical mitral prosthetic valves 16. Known adverse reaction to adenosine. 17. Chronic Kidney Disease ≥ Stage 4. 18. Significant congenital heart disease (including atrial septal defects or pulmonary vein abnormalities; however, subjects with patent foramen ovale will not be excluded). 19. Pregnant subjects. 20. Cerebral ischemic event (stroke or transient ischemic attack) in the six months prior to consenting for the trial. 21. History of thromboembolic events in the 6 months preceding enrollment. 22. Currently participating or anticipated to participate in interventional clinical trials of drug, device or biologic agents that could affect the results of this trial. 23. Primary pulmonary hypertension 24. Rheumatic heart disease 25. Thrombocytosis, thrombocytopenia and other hypercoagulable states 26. Active systemic infection 27. Patients with life expectancy less than 12 months. 28. Unwilling or unable to comply fully with study procedures and follow-up.